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ANTIFLAMMIN-2 (AF2) is a nonapeptide corresponding to
the amino acid residues 246-254 of lipocortin-1 showing
anti-inflammatory activity both in vitro and in vivo. The
effect ofAF2 on the thromboxane B2 (TXB2) and histamine
release from isolated and perfused guinea-pig lungs has
been studied. AF-2 (10-100 nM) inhibited leukotriene C4-
(LTC4) (3 ng) and antigen-induced (ovalbumin, 1 mg)
TXB release in normal and sensitized lungs, respectively.
In contrast AF-2 (100 nM) did not modify TXB2 release
induced by histamine (5 lag) or bradykinin (5 lag) in nor-
mal lungs. Antigen-induced histamine release was not
affected by 100 nM AF-2 infusion. When tested in chopped
lung fragments AF-2 (0.1-25 laM) did not modify the
release of histamine and TXB2 induced by antigen (oval-
bumin, 10 lag m1-1) or calcium ionophore A 23187 (1 laM).
Our results show that the inhibitory effect ofAF-2 on TXB2
release is selective and depends on the stimulus applied.
In this respect AF-2 mimics, at least in part, the actions
of both glucocorticoids and lipocortin-1.
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Introduction
Uteroglobin and lipocortin-12 belong to a family
of structurally related proteins referred to as
annexins or lipocortins which are calcium-binding
proteins.
3-s Lipocortins are glucocorticoid-indu-
cible proteins which, by inhibiting phospholipase
A2 (PLA2), are believed to be involved in the
suppression of prostaglandin and leukotriene
synthesis associated with some aspects of the
anti-inflammatory activity of corticosteroids.
6
Recently nonapeptide fragments of uteroglobin
and lipocortin-1, named antiflammins,7 have
been shown to inhibit PLA2 in vitro and to
possess anti-inflammatory activity in vivo.7-9 One
of these nonapeptides, antiflammin-2 (AF-2,
HDMNKVLDL) corresponds to the amino acid
residues 246-254 of lipocortin-l.7 However,
conflicting results have been reported concerning
the biological activity of AF-2. The peptide has
been shown to inhibit carrageenan-induced rat paw
oedema,
9 porcine pancreatic PLA27 and human
polymorphonuclear leucocyte PLA2 activity as well
as PEA2 activity in extracts of human psoriatic
epidermis.
1 In contrast, other authors have
reported that AF-2 is unable to inhibit porcine
PLA2, eicosanoid-release by different cell types, and
carrageenan-induced rat paw oedema.
>3
In the light of these conflicting results we decided
to evaluate the biological activity of AF-2 in the
isolated perfused guinea-pig lung model where
human recombinant lipocortin-1 has been shown to
be very active in inhibiting LTC4-induced TXB2
(C) 1992 Rapid Communications of Oxford Ltd
release.4 We have also tested the effect of the
peptide on histamine release in the same experi-
mental model.
Materials and Methods
Animals: Male guinea-pigs (Dunkin Hartley,
300-400g) were used. In some experiments
animals were sensitized by subcutaneous and
intraperitoneal injections of equal doses (100 mg)
of ovalbumin
15 and the lungs were then removed
.3 weeks later.
Mediator releasefrom perfused lungs: Lungs from normal
or sensitized guinea-pigs were cannulated through
the pulmonary artery, excised and suspended in a
chamber where they were immediately perfused
with oxygenated Krebs bicarbonate solution at
37C using a Watson and Marlow 503 S peristaltic
pump. The rate of perfusion was constant at
5 ml min -1. AF-2 was infused at 0.1 ml min
-1
30min before stimulating TXB2 or histamine
release and throughout the experiment. Fractions of
5 ml, corresponding to a 1 min collection time, were
collected and stored at -80C for assay. Stimuli
such as LTC4 (3 ng), ovalbumin (1 mg), histamine
(5/g) or bradykinin (5/g) were applied as a bolus
injection (0.1 ml).
Mediator release from chopped lungs: Lungs from normal
or sensitized male guinea-pig were cannulated and
perfused with Krebs bicarbonate as described
above. Lungs were then removed, cut into small
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pieces with a sharp blade and washed extensively.
Triplicate samples (0.6 g wet weight) were
incubated in Krebs bicarbonate solution at 37C
for 10 min in the presence of AF-2 (0.1-25
and subsequently challenged with ovalbumin
(10/g/m1-1 sensitized lungs) or calcium iono-
phore A23187 (1/4M, normal lungs). The incuba-
tion was stopped 30 min later by transferring
the samples to an ice bath. Incubation media were
then centrifuged (50 g) and aliquots for TXB2
and histamine determination immediately frozen
and kept at -80C until analysis. Lung fragments
were resuspended in Krebs bicarbonate solution,
boiled for 10 min and filtered. The filtrate was
centrifuged (50 g’) and aliquots for histamine
assay were kept at -80C until analysis.
In some experiments lungs were cannulated in
situ through the pulmonary artery and perfused
with AF-2 for 30 min. The lungs were then rapidly
removed, cut into small pieces and incubated and
processed as described above.
Radioimmunoassay of thromboxane Be: Thromboxane .B2
was measured by radioimmunoassay without prior
extraction or purification as previously described
16
and expressed as ng min- in perfusion
experiments.
Fluorimetric anasis of histamine: Histamine release was
measured fluorimetrically
17 and corrected for
spontaneous release occurring in the absence of the
inducer and expressed as/g min-1 in the perfusion
experiments.
Since it has been reported that a reduction of
the biological activity of AF-2 is caused by the
oxidation of the methionine residue some experi-
ments were performed in the presence of
dithiothreithol (10:1). However, we could not
detect any diflerences in AF-2 activity.
Materials: The composition of Krebs bicarbonate
solution (mM) was the following: NaC1 118, KC1
4.7, KH2PO4 1.2, MgSO4.7H20 1.17, CaCl2.6H20
0.25 and glucose 8.4. Other agents used were:
calcium ionophore A23187 (Calbiochem), ovalbu-
min grade II, histamine hydrochloride, bradykinin,
TXB2, LTC4 (Sigma); phtaldialdeyd (Fluka), radio-
labelled TXB. (Amersham). AF-2 was a generous
gift from Dr P. Doyle (Wellcome Foundation,
Beckenham, UK). Antibody anti-TXB2 was kindly
supplied by Dr J. Salmon (Wellcome, UK).
Results
Mediator release from perfused lungs" The basal release
of TXB2 from isolated perfused normal guinea-pig
lungs was 6.35 -f- 1.8 ng min -1", n- 12. The basal
release was not aEected by 10nM AF-2
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FIG. 1. Time course of TXB2 release from isolated and perfused normal
guinea-pi9 lungs challenged with bolus injection of LTC4 (3
Control ((C)). AF-2 was infused at 10 (0), a0 (A) and ]00 nM ().
ach oint reresents the mean S (vertical bars) of four lungs.
1.7 ngmin-1; n- 4) and 100nM AF-2 (7.35-f-
0.8 ng rain-" n 4)
Normal guinea-pig lungs challenged with a bolus
injection of 3 ng LTC4 released large amounts of
TXB2 (Fig. 1). The peak response was observed 2
min after the challenge (289 -k 6 ng min-; n 4),
thereafter the TXB2 release rapidly declined to a
low level after 10 min (16 10 ng min-1; n- 4).
When the lung was infused with AF-2 the
LTC4-induced TXB2 release was greatly reduced
throughout the time course of the response (Fig. 1).
The peak response was reduced by the peptide in a
concentration-related fashion as inhibition of 36%,
54% and 61% were induced by 10, 30 and 100 nM
infusion of AF-2.
In contrast, neither the time course nor the peak
response of the TXB2 release induced by histamine
(5 #g) or bradykinin (5/4g) in normal lungs were
aEected by infusion of AF-2 up to 100 nM. In fact,
the peak of TXB2 release from lungs challenged
with histamine (75_-t-2.8ngmin-l", n-4) was
unat:fected by 100nM AF-2 infusion (82-F
2 ng min-l"n, --4), as the peak of TXB2 release
from lungs challenged with bradykinin (78-f-
13 ng min-l" n 4)
However the antigen-induced release of TXB2
from sensitized lungs was reduced by 100 nM AF-2
(Fig. 2A). The peak release, which was ten-fold
higher than that obtained with other stimuli
(635 39 ng min-l"n, -6), was significantly in-
hibited by 32% (431 -t- 8.7ngmin-1; n-6).
Thromboxane Be release from sensitized un-
challenged lungs (14.5 -k 1.6 ng min-1., n 4) was
not affected by 100nM infusion AF-2 (13.4-k
1.1ngmin-l" n=4)
Antiflammin-2 infusion (100 nM) did not modify
either the peak response or the time course of the
antigen-induced histamine release from sensitized
lungs (Fig. 2B).
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FIG. 2. Time course of TXB2(A) and histamine (B) release from isolated and perfused sensitized guinea-pig lungs challenged with a bolus injection of
antigen (ovalbumin mg). Control ((C))’ infusion of AF-2 100 nM (O). Each point represents the mean _+ SE (vertical bars) of six lungs.
Mediator release from chopped lungs: In another set of
experiments we evaluated the effect of AF-2
infusion on the release ofTXB2 and histamine from
chopped guinea-pig lungs. The mediators were
released from normal lungs by 1/M calcium
ionophore A23187 and by antigen (10/2gm1-1
ovalbumin) from sensitized lungs. None of the
AF-2 concentrations tested (0.1-25/M) was able to
significantly modify TXBp. and histamine released
induced by these agents. Similar results were
obtained when lungs were perfused in situ
with AF-2 at the above concentrations and
fragments subsequently challenged with the same
stimuli (data not shown).
Discussion
These data show the ability of AF-2 to inhibit the
TXB2 release induced by LTC4 or antigen in normal
and sensitized guinea-pig lungs respectively. How-
ever, when other stimuli, such as histamine and
bradykinin were used, no inhibition ofTXB2 release
was observed.
Human recombinant lipocortin-1 (annexin-1)
when infused through normal guinea-pig lung
preparation inhibited LTC4-induced TXB2 release.
14
Glucocorticoids have been shown to inhibit TXBp.
release from guinea-pig isolated perfused lungs
challenged by different stimuli such as leukotrienes,
histamine or antigen while they did not prevent
TXB2 generation induced by bradykinin.
18
For these reasons we studied the effect of the
nonapeptide, referred to as antiflammin-2, corre-
sponding to lipocortin-1 sequence 246-254, on
TXB2 generation from guinea-pig lungs challenged
with different stimuli in order to compare its
biological activity to the effect of glucocorticoids
and lipocortin-1.
Our results suggest that the inhibitory activity of
AF-2 on TXB2 release is dependent on the challenge
used and mimics, at least in part, the action of both
glucocorticoids and lipocortin-1. In fact AF-2, like
glucocorticoids, significantly inhibits TXB2 release
induced by EWe4 and it is unable to block the
releasing action of bradykinin in normal lungs. In
this respect it is interesting to observe that
dexamethasone has an inhibitory activity on the
bradykinin-induced eicosanoid release from the
inflamed lungs while it is ineffective in normal
lungs.
19 The reason for the lack of activity of both
glucocorticoids and AF-2 in normal lungs is not
clear.
It has been suggested that separated PLA2 pools
may exist or that a phospholipase C linked pathway
could be involved. 18’2 The main difference between
AF-2 and dexamethasone was observed when the
lung vas stimulated with histamine. In fact AF-2
was unable to block the histamine-induced TXB2
release in normal lungs, which has been reported to
be inhibited by glucocorticoids.
8 We found that
AF-2 was unable to inhibit the antigen-induced
histamine release from sensitized lungs. This
observation is consistent with previous results
reported by us suggesting that another glucocorti-
cold-induced protein (vasocortin) different from
lipocortin
2 is responsible for the glucocorticoid
inhibition of histamine release.
22
The release for the conflicting results reported by
different authors on the biological activity of AF-2
is not clear. In fact, the mode of action of
lipocortins and lipocortin-derived peptides as PLA2
inhibitors it is not yet understood. Thus until now
it has not been clearly demonstrated if the PLA2
inhibition depends on a direct interaction between
the enzyme and the inhibitor or it is due to the
binding of the inhibitor to the substrate.
23
Another aspect which could affect the biological
activity of the peptide might be its oxidation
possibly occurring during the experimental proce-
dures. In fact it has been suggested that AF-2 might
be inactivated by spontaneous oxidation of its
methionine residue in the position 3 and con-
sequently it might be effective only in the presence
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of a reducing agent. In this respect we
did not observe any significant difference in the
inhibition of TXB2 release by AF-2 in the presence
or absence of dithiothreitol.
Furthermore the inhibitory action of AF-2 on
TXB2 generation seems to be dependent not only
on the stimulus but also on the experimental model
used. Indeed, the peptide was completely ineffective
when assayed on TXB2 release from chopped lungs.
Corticosteroids are very powerful drugs in
asthma therapy but their mechanism is not yet
clearly understood and their clinical use mostly
empirical. Antiflammin-2 could be used as a useful
tool in exploring the mechanism through which
glucocorticosteroids could affect the airway re-
gulatory mechanisms.
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